Hanmi Pharm Co Ltd (128940) — Cash Flow-to-Debt Ratio
Hanmi Pharm Co Ltd (128940) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of ₩42.02 Billion could theoretically repay 0% of its total liabilities (₩694.79 Billion) in one year. See 128940 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hanmi Pharm Co Ltd Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Hanmi Pharm Co Ltd across 15 annual periods. For the full cash flow conversion analysis, see 128940 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Hanmi Pharm Co Ltd (2010–2024)
Year-by-year debt coverage analysis for Hanmi Pharm Co Ltd. Check Hanmi Pharm Co Ltd (128940) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.25x | ₩193.49 Billion | ₩780.09 Billion | ▼ -8.5% |
| 2023 | 0.27x | ₩216.54 Billion | ₩798.46 Billion | ▲ +53.0% |
| 2022 | 0.18x | ₩162.27 Billion | ₩915.36 Billion | ▼ -11.5% |
| 2021 | 0.20x | ₩201.92 Billion | ₩1.01 Trillion | ▲ +38.8% |
| 2020 | 0.14x | ₩151.53 Billion | ₩1.05 Trillion | ▲ +1165.4% |
| 2019 | 0.01x | ₩12.45 Billion | ₩1.09 Trillion | ▼ -60.4% |
| 2018 | 0.03x | ₩25.98 Billion | ₩901.95 Billion | ▲ +139.8% |
| 2017 | -0.07x | ₩-62.91 Billion | ₩868.51 Billion | ▼ -115.1% |
| 2016 | 0.48x | ₩412.97 Billion | ₩862.45 Billion | ▲ +360.3% |
| 2015 | 0.10x | ₩101.71 Billion | ₩977.78 Billion | ▲ +240.8% |
| 2014 | -0.07x | ₩-32.82 Billion | ₩444.09 Billion | ▼ -135.9% |
| 2013 | 0.21x | ₩85.99 Billion | ₩417.95 Billion | ▲ +38.6% |
| 2012 | 0.15x | ₩63.27 Billion | ₩426.25 Billion | ▼ -0.8% |
| 2011 | 0.15x | ₩61.30 Billion | ₩409.53 Billion | ▲ +233.7% |
| 2010 | 0.04x | ₩18.94 Billion | ₩422.34 Billion | — |